Table 2.
Comparison of the groups with regard to anorectal complication development.
| Anorectal complication
|
P value | ||
|---|---|---|---|
| Yes (n=34) | No (n=45) | ||
|
| |||
| Gender | 0.670 | ||
| • Male | 22 (64.7%) | 27 (60.0%) | |
| • Female | 12 (35.3%) | 18 (40.0%) | |
|
| |||
| Diagnosis | 0.009 | ||
| • Acute leukemia and myelodysplastic syndrome | 29 (85.3%) | 24 (53.3%) | |
| • Lymphoma and multiple myeloma | 5 (14.7%) | 18 (40.0%) | |
| • Aplastic anemia | 0 | 3 (6.7%) | |
|
| |||
| Number of comorbidity | 0.753 | ||
| • No | 26 (76.5%) | 31 (68.9%) | |
| • 1 | 7 (20.6%) | 12 (26.7%) | |
| • 2 | 1 (2.9%) | 2 (4.4%) | |
|
| |||
| Active disease | 0.015 | ||
| • Yes | 23 (67.6%) | 18 (40.0%) | |
| • No | 11 (32.4%) | 27 (60.0%) | |
|
| |||
| ECOG performance status | 0.766 | ||
| • 0 | 8 (23.5%) | 14 (31.1%) | |
| • 1 | 19 (55.9%) | 25 (55.6%) | |
| • 2 | 4 (11.8%) | 4 (8.9%) | |
| • 3 | 3 (8.8%) | 2 (4.4) | |
|
| |||
| Type of treatment | 0.0001 | ||
| • Chemotherapy | 30 (88.2%) | 13 (28.9%) | |
| • Hematopoietic stem cell transplantation | 3 (8.8%) | 32 (71.1%) | |
| • Other | 1 (2.9%) | 0 | |
|
| |||
| Febrile neutropenia | 0.344 | ||
| • No | 6 (17.6%) | 12 (26.7%) | |
| • Yes | 28 (82.4%) | 33 (73.3%) | |
|
| |||
| Use of corticosteroid | 14 (41.2%) | 14 (31.1%) | 0.354 |
|
| |||
| History of anorectal disease before diagnosis of the hematologic disease | 0.005 | ||
| • No | 20 (58.8%) | 40 (88.9%) | |
| • Yes | 14 (41.2%) | 5 (11.1%) | |
|
| |||
| Death | 0.059 | ||
| • No | 20 (58.8%) | 35 (77.8%) | |
| • Yes | 14 (41.2%) | 10 (22.2%) | |